葡萄膜炎市場：全球市場展望、流行病學、競爭格局與市場預測報告（32個主要市場），2025-2035年

市場概覽

• 中國葡萄膜炎市場預計將從2025年的約 8,070萬美元成長到2035年的近 9,730萬美元，呈現逐步擴張的態勢。
• 以下因素推動市場成長：
• 生物製藥和非類固醇免疫調節療法的廣泛應用
• 改善慢性病和復發性疾病的診斷和長期管理
• 市場規模的擴大是由治療週期延長和先進眼科治療方法的日益普及所推動的。
• 未來市場成長將取決於標靶免疫療法的發展、更安全的長期治療策略以及難治性葡萄膜炎治療的改善。

葡萄膜炎概述

葡萄膜炎是一組包括葡萄膜系統的異質性眼內發炎性疾病，包括虹膜、睫狀體和脈絡膜。從解剖學角度來看，葡萄膜炎可分為前葡萄膜炎、中間葡萄膜炎、後葡萄膜炎和全葡萄膜炎，其中前葡萄膜炎最常見。其病理生理機轉包括皰疹病毒、弓漿蟲病、結核病和梅毒等感染因素，以及非感染性的免疫介導機轉。後者通常與HLA-B27相關性脊椎關節病變、類肉瘤病、白塞氏症、幼年特發性關節炎和多發性硬化症等全身性疾病有關。患者可能出現眼痛、眼紅、畏光、視力下降和飛蚊症等症狀，這些症狀因病變部位而異。另一方面，慢性或後葡萄膜炎進展緩慢，可透過白內障、青光眼、囊性黃斑部水腫和視網膜剝離威脅視力。診斷包括綜合裂隙燈顯微鏡檢查、散瞳眼底檢查、光學同調斷層掃描（OCT）和螢光造影，以及針對感染或自體免疫病因的全身檢查。非感染性疾病的治療基礎仍是皮質類固醇（局部、眼眶周圍或全身性用藥），而對於慢性或復發性疾病，則使用非類固醇免疫調節劑，例如胺基甲基葉酸、黴酚酸酯和Azathioprine。在難治性病例中，使用生物製藥，特別是Adalimumab，一種專門用於治療非感染性葡萄膜炎的抗TNF藥物。預後取決於病因、解剖部位和治療反應。多學科協作、定期眼科後續觀察和患者教育對於維持視力和生活品質非常重要。

主要亮點

• 預計到2025年，中國葡萄膜炎患者總數將約為 3,611,621 人，到2035年將增加至近 3,754,973 人，反映出疾病負擔日益加重。
• 在所有被診斷出患有此病的患者中，前葡萄膜炎仍然是最常見的臨床亞型。
• 慢性及復發性發炎仍然是長期視力障礙和生活品質下降的主要原因。
• 免疫抑制療法和生物製藥的廣泛應用改善難治性非感染性葡萄膜炎的治療。
• 早期診斷和多學科疾病管理對於預防不可逆的眼部併發症仍然非常重要。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化在 32個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

主要企業

• Priovant Therapeutics, Inc.
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Eli Lilly and Company

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要治療方法 - 概述及關鍵意見領袖見解
• 新興治療方法
• 重點
• 值得關注的後期新興治療方法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章 未滿足的需求與目標產品分析

• 主要未滿足需求及新興療法的未來成就前景
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Global Uveitis Disease Market Outlook

Thelansis's "Global Uveitis Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uveitis Disease treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Uveitis Disease Overview

Uveitis is a heterogeneous group of intraocular inflammatory disorders affecting the uveal tract - iris, ciliary body, and choroid - classified anatomically as anterior, intermediate, posterior, or panuveitis, with anterior uveitis representing the most prevalent form. The pathophysiology encompasses both infectious triggers - including herpesviruses, toxoplasma, tuberculosis, and syphilis - and non-infectious immune-mediated mechanisms, the latter frequently associated with systemic conditions including HLA-B27-associated spondyloarthropathies, sarcoidosis, Behcet disease, juvenile idiopathic arthritis, and multiple sclerosis. Patients present with painful red eye, photophobia, blurred vision, and floaters - symptoms varying with anatomical location - while chronic or posterior uveitis may progress insidiously, threatening vision through cataract, glaucoma, cystoid macular oedema, and retinal detachment. Diagnosis integrates slit-lamp biomicroscopy, dilated fundoscopy, optical coherence tomography, fluorescein angiography, and targeted systemic workup to identify infectious or autoimmune aetiology. Corticosteroids - topical, periocular, or systemic - remain the therapeutic cornerstone for non-infectious disease, with steroid-sparing immunomodulators including methotrexate, mycophenolate, and azathioprine employed for chronic or recurrent disease. Biologics - particularly anti-TNF agents adalimumab, approved specifically for non-infectious uveitis - are utilised in refractory cases. Prognosis varies with aetiology, anatomical location, and treatment response; multidisciplinary collaboration, regular ophthalmological monitoring, and patient education are essential to preserving vision and quality of life.

Key Highlights

• In China, total prevalent uveitis cases are projected to increase from approximately 3,611,621 in 2025 to nearly 3,754,973 by 2035, reflecting a growing disease burden.
• Anterior uveitis remains the most common clinical subtype across diagnosed patient populations.
• Chronic and recurrent inflammation continues to contribute significantly to long-term visual impairment and reduced quality of life.
• Increasing use of immunosuppressive therapies and biologics is improving disease control in refractory non-infectious uveitis.
• Early diagnosis and multidisciplinary disease management remain critical to preventing irreversible ocular complications.

Market Overview

• The China uveitis market is projected to grow from approximately $80.70 MN in 2025 to nearly $97.30 MN by 2035, reflecting moderate market expansion.
• Market growth is supported by:
• Increasing adoption of biologics and steroid-sparing immunomodulatory therapies
• Improved diagnosis and long-term management of chronic and recurrent disease
• Market value growth is driven by rising treatment duration and increasing utilization of advanced ophthalmic therapies.
• Future market growth will depend on development of targeted immunotherapies, safer long-term treatment strategies, and improved management of refractory uveitis.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Priovant Therapeutics, Inc.
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Eli Lilly and Company

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)